Side effects of pegvisomant include reactions at the injection site, swelling of the limbs, chest pain, [[hypoglycemia]], nausea and [[hepatitis]].<ref>{{Cite journal |doi=10.1530/eje.1.02160 |pmid=16728538 |title=Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant |journal=European Journal of Endocrinology |volume=154 |issue=6 |pages=805â€“6 |year=2006 |last1=Feenstra |first1=J |last2=Van Aken |first2=M. O. |last3=De Herder |first3=W. W. |last4=Feelders |first4=R. A. |last5=Van Der Lely |first5=A. J. }}</ref>

 


 
Blocking of the growth hormone receptor reduces feedback control of the growth hormone regulation, leading to approximately doubled GH levels.<ref>{{cite journal |doi=10.1186/1472-6823-9-20 |pmid=19814797 |pmc=2768727 |title=Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: A systematic review and economic evaluation |journal=BMC Endocrine Disorders |volume=9 |pages=20 |year=2009 |last1=Moore |first1=David J |last2=Adi |first2=Yaser |last3=Connock |first3=Martin J |last4=Bayliss |first4=Sue }}</ref>

 

